跳至主要内容
临床试验/NCT04645641
NCT04645641Unknown不适用

Evaluation of the Safety and Effectiveness of the Dexcom Glucose Monitoring (CGM)

DexCom, Inc.8 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2020年10月12日最近更新:
适应症

试验速览

阶段
不适用
发起方
DexCom, Inc.
入组人数
150
试验地点
8
主要终点
System Performance

研究概览

简要总结

Evaluation of the Safety and Effectiveness of the Dexcom Glucose Monitoring (CGM) System

详细描述

The objective of the study is to establish performance of the Dexcom CGM System (System) in comparison to a blood glucose comparator method.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

盲法说明

All systems worn will be blinded. Sensor wear locations will be pre-assigned. All sensor insertions will be performed at the clinic by study staff.

入排标准

年龄范围
2 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ages 2 or older
  • Diagnosis of Type 1 diabetes or Type 2 diabetes
  • Willing to wear the required number of Systems for the total duration of study wear
  • Willing to participate in Clinic Session(s) during study wear

排除标准

  • Presence of extensive skin changes/diseases at sensor wear site(s) that preclude wearing the sensor(s) on skin
  • Known allergy to medical-grade adhesives
  • Pregnancy
  • Hematocrit outside specification
  • ≥ 18 years of age:
  • Male: 36.0%;
  • Female: 33.0%;
  • 13-17 years of age: 35.0%;
  • 7 years - 12 years of age: 32.0%;
  • End stage renal disease and currently managed by dialysis or anticipating initiating dialysis during the study wear period
  • Required or scheduled to have a Magnetic Resonance Imaging (MRI) scan, Computed Tomography (CT) scan, or diathermy during the study wear period

结局指标

主要结局

System Performance

时间窗: 10 days

System Performance will be characterized with respect to comparator venous plasma measurements.

次要结局

  • System Related Adverse Device Effects(10 days)

研究者

发起方
DexCom, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验

Evaluation of the Safety and Effectiveness of the... | 临床试验